AptaBio Therapeutics Inc

AptaBio Therapeutics Inc has a market capitalization of KRW 184.85 billion and a price-to-book ratio of 3.21, indicating that the market values the company at a premium to its book value. The company's liquidity position is characterized by KRW 26.08 billion in cash and equivalents, but it also carries KRW 45.43 billion in long-term debt, resulting in a debt-to-equity ratio of 0.79. The company's operating cash flow is negative at KRW -2.46 billion, and its free cash flow is also negative at KRW -3.85 billion, suggesting that the company is not generating sufficient cash from operations to fund its activities.

In terms of profitability, AptaBio Therapeutics Inc reported a net income of KRW -39.67 billion and an operating income of KRW -31.11 billion, indicating significant losses. The company's return on equity is -6.9%, and its return on assets is -4.41%, both of which are well below the industry median for biotechnology firms. The company's gross profit of KRW 74.75 million is minimal compared to its revenue of KRW 637.23 million, suggesting that the company is struggling to maintain profitability.

AptaBio Therapeutics Inc's revenue is not segmented by geographic region or product line in the available data, but the company's operations are likely concentrated in the biotechnology sector, which is characterized by high research and development (R&D) costs and long development cycles. The company's financial performance is not supported by disclosed revenue concentration data, but the biotechnology industry is known for its high degree of specialization and reliance on a limited number of products or therapies.

The company's growth trajectory is not clearly defined in the available data, but the significant losses and negative cash flows suggest that the company is in an early stage of development or facing challenges in commercializing its products. The company's revenue of KRW 637.23 million is relatively small, and there is no indication of a clear growth path or expansion strategy in the available data. The company's financial performance is not supported by disclosed growth metrics, but the biotechnology industry is known for its high volatility and long-term investment horizon.

The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The company's negative net cash position after subtracting total debt is a key flag, indicating that the company may face liquidity constraints in the near term. The company's dilution risk is low, but the potential for dilution remains a concern due to the company's high debt levels and negative cash flows. The company's financial performance is not supported by disclosed dilution risk factors, but the biotechnology industry is known for its high capital requirements and potential for equity dilution.

Recent events related to AptaBio Therapeutics Inc are not disclosed in the available data, but the company's financial performance and risk profile suggest that it is in a development phase with significant financial challenges. The company's financial performance is not supported by disclosed recent events, but the biotechnology industry is known for its high degree of innovation and regulatory scrutiny.

Revenue grew 10% year-over-year to KRW 3.7 billion, demonstrating top-line expansion despite ongoing operational losses.

Free cash flow improved by 45.2% year-over-year, indicating better cash generation efficiency in the latest fiscal period.

Long-term debt decreased significantly from KRW 7.5 billion to KRW 4.4 billion, reducing leverage and financial risk.

Dilution risk is assessed as low, suggesting limited immediate threat to shareholder equity value from share issuance.

The company faces high credit risk, signaling potential difficulties in meeting financial obligations or securing favorable financing.

Net margin of -6.2% is significantly worse than the biotechnology cohort median of -2.4%, indicating poor profitability.

Debt-to-equity ratio of 0.79 places the company in the bottom quartile compared to peers, reflecting high leverage.

Operating margin of -4.9% trails the cohort median of -2.6%, highlighting inefficiencies in core business operations.

Medium liquidity risk suggests potential challenges in meeting short-term financial obligations without additional capital.